Abstract 1660P
Background
Pancreatic cancer (PC) is among the deadliest malignancies with a 5-year survival rate of nearly 12%. Malignant proliferating cancer cells usually exhibit metabolism reprogramming, which is distinct from their normal counterparts, resulting in therapeutic vulnerabilities. However, the underlying mechanisms of aberrant cholesterol metabolism regulating PC progression are poorly understood. In the present study, we aimed to identify and investigate the role of a key cholesterol metabolic enzyme squalene epoxidase (SQLE) in tumorigenesis of PC.
Methods
Integrating analysis of The Cancer Genome Atlas (TCGA) cohort and multiple Gene Expression Omnibus (GEO) datasets was used to find the top up-regulated cholesterol homeostasis-related gene in PC. The IHC staining of tissue microarray composed of human PC samples were used to identify the clinical significance of SQLE in PC patients. The biological functions of SQLE and the potential therapeutic efficiency of SQLE inhibitors were assessed both in vitro and in vivo. Transcriptome analysis, untargeted metabolomics analysis, and related lipid detection were further performed to clarify the molecular mechanism of SQLE on PC development.
Results
We found SQLE expression was highly expressed in PC tissues compared with normal pancreatic tissues, and the upregulated SQLE predicted poor outcomes in PC patients. Additionally, we demonstrated that SQLE promoted the growth of PC both in vitro and in vivo. Mechanistically, inhibition of SQLE caused squalene accumulation-induced endoplasmic reticulum (ER) stress occurrence and subsequent cell apoptosis. Moreover, SQLE increased cholesterol de novo biosynthesis and maintained the stability of lipid rafts, which in turn activated Src/PI3K/Akt signalling. Finally, we found that pharmacological blockade of SQLE with terbinafine or NB-598 profoundly suppressed PC cell proliferation and xenograft tumor growth.
Conclusions
Our findings demonstrated the oncogenic role and tumor promoting mechanism of SQLE in PC. SQLE promotes PC growth by attenuating ER stress and promoting lipid rafts-regulated Src/PI3K/Akt signaling pathway, suggesting SQLE as a potential therapeutic target for PC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-002), the National High Level Hospital Clinical Research Funding (2022-PUMCH-D-001), the National Natural Science Foundation of China (82102810) and the fellowship of China Postdoctoral Science Foundation (2021M700501; 2022T150067).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22